AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01503320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral glutamine
Description: Dosage of glutamine: 0.57g/kg, \~ 30g/day= 3sachets
Study NCT01503320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar appearing nutritional supplement without glutamine.
Study NCT03903081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114
Study NCT01573598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given orally, once per day
Study NCT01573598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone, 20 mg per day, oral administration
Study NCT01573598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone, 40 mg once per day, oral administration
Study NCT01970358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Study NCT01970358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptides
Study NCT02265341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03030378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy
Study NCT03030378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT02540447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Purge
Description: In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
Study NCT00685490 — intervention group
Intervention type: PROCEDURE
Intervention: Vitrectomy w/o ILM peeling for macular edema with BRVO
Description: Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
Study NCT03030378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT03030378 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Edodekin alfa
Description: Given SC
Study NCT03030378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo a MRI
Study NCT03030378 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02694549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CaveoVasc
Study NCT05449093 — intervention group
Intervention type: OTHER
Intervention: Periodontal clinical measurements and gingival crevicular fluid sampling
Description: Periodontal clinical meaurements including the probing depth, clinical attachment loss, the dichotomous recording (present/absent) of bleeding on probing, gingival index, and the plaque index at six sites (distobuccal, buccal, mesiobuccal, distopalatinal/lingual, palatinal/lingual, mesiopalatinal/lingual) on all teeth, except third molars, were performed using manuel periodontal probe.~Standardized absorbent paper strips were used for gingival crevicular fluid sampling. A sterile paper strip was gently inserted into the gingival sulcus/periodontal pocket until mild resistance was felt and were kept in place for 30 seconds. The absorbed fluid volume was measured by a precalibrated electronic device.
Study NCT05612282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: body composition analysis
Description: A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer
Study NCT03030378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan
Study NCT01364350 — intervention group
Intervention type: OTHER
Intervention: standard of care in general clinical practice
Description: Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
Study NCT01095575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline 3 ml, morphine 3mg
Description: On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
Study NCT05216848 — intervention group
Intervention type: OTHER
Intervention: Wijma Delivery Expectancy Questionnaire
Description: Simple questionaire identifying the level of fear of childbirth in pregnancy
Study NCT02734056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Listening to music that the patient likes
Study NCT02734056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Control
Study NCT04779333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAP
Description: LEAP will be delivered through the typical 9 weekly BMT group sessions lasting 90 minutes. Plus wrist worn activity tracker \& facebook group.
Study NCT05612282 — intervention group
Intervention type: OTHER
Intervention: anthropometric measurements
Description: An assessment of the status of nutrition based on anthropometric measurements was carried out.
Study NCT05612282 — intervention group
Intervention type: OTHER
Intervention: Interview questionnaire
Description: An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.
Study NCT04779333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard BMT
Description: Weekly BMT groups sessions which follow the Barkley curriculum
Study NCT04219930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Expression of nucleotide protein -3
Description: Expression of nucleotide protein -3 will be measured in serum by ELISA
Study NCT05612282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical parameters
Description: The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.
Study NCT00486759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study NCT05216848 — intervention group
Intervention type: OTHER
Intervention: Clinical data collection
Description: Collection of the standard clinical data during hospitalization
Study NCT00486759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study NCT01274741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creating Change (CC)
Description: Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format. The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
Study NCT01274741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seeking Safety (SS)
Description: Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD. It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders. In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
Study NCT00486759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study NCT00486759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study NCT00486759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study NCT00486759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study NCT01181180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: water consumption
Description: The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
Study NCT01181180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water consumption
Description: The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
Study NCT03635294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: combining genomics, transcriptomics, metabolomics and morphological analyses performed on induced pluripotent stem cell (iPSC)-derived neural cells
Study NCT05250336 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Description: Assessment of Prognostic and Predictive value of Tumor-Infiltrating Lymphocytes and Programmed cell Death - Ligand 1 in Breast cancer
Study NCT04313543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose and Longan syrup
Description: Volunteers take 50 g of glucose in 250 ml of water in 5 minutes. Then, they take 50g of longan syrup in 250 ml of water in 5 minutes
Study NCT00573339 — intervention group
Intervention type: OTHER
Intervention: Cardiac MRI
Description: up to 3 Cardiac MRI scans per participant in 1-4 months
Study NCT01063036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 1 mg, once daily, 96 weeks
Study NCT01063036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tablets, Oral, 300 mg, once daily, 96 weeks
Study NCT02293018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% (w/w) MTC896 Gel Once Daily
Study NCT02293018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% (w/w) MTC896 Gel Twice Daily
Study NCT02293018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% (w/w) MTC896 Gel Once Daily
Study NCT06336486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent pneumatic compression +pregabalin group
Description: The investigators divided the patients into two equal groups , some of the patients were given an intermittent pneumatic compression program at a pressure of 35 mmhg for 30 min to the lower extremity for 10 days of extreme alternation in our clinic and pregabalin treatment was continued.
Study NCT06336486 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pregabalin group
Description: only pregabalin treatment was continued.
Study NCT00178399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Study NCT02814643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
Study NCT02814643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benralizumab Placebo
Description: Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
Study NCT02814643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonal influenza virus vaccine
Description: Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
Study NCT02814643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Seasonal influenza virus vaccine
Description: Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
Study NCT02195713 — intervention group
Intervention type: DEVICE
Intervention: Accuryn
Description: Accuryn is a novel electronic urine output monitor
Study NCT02356549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMR Tailoring
Description: Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
Study NCT02356549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey Tailoring
Description: Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
Study NCT02356549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Involvement
Description: Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
Study NCT04847219 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Professional flash glucose mornitoring
Description: Subjects will use Professional flash glucose mornitoring once a month for 3 months.
Study NCT05612282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary fitness test
Description: Cardiopulmonary fitness was assessed using the Modified Bruce protocol
Study NCT04847219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal flash glucose mornitoring
Description: Subjects will use Personal flash glucose mornitoring once a month for 3 months.
Study NCT02391207 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatic vein-sparing hepatectomy
Description: HV detachment, partial resection and section on the basis of HV-CLM relationship
Study NCT05612282 — intervention group
Intervention type: OTHER
Intervention: nutritional interview
Description: A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.
Study NCT02958345 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Vaccination with one dose of Zostavax per Zostavax package insert
Study NCT02958345 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of 0.65 mL of sterile normal saline
Study NCT02416076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment at EL2
Description: Focused ultrasound energy delivered below the surface of the skin.
Study NCT02416076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment at EL4
Description: Focused ultrasound energy delivered below the surface of the skin.
Study NCT04887103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water application
Description: Pregnant women will apply hot water to their legs before going to sleep for a week.
Study NCT03919864 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CONNECT Intervention
Description: Participants will be included in a multi-component e-tool with brief educational videos, an assessment of multidimensional supportive care needs, a tailored resource list and an optional automated referral to a caregiver navigator. Two weeks after baseline participants will receive re-education and an optional referral.
Study NCT01848054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone sublingual tablets
Description: Advanced-formulation buprenorphine/naloxone sublingual tablets
Study NCT01848054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone sublingual tablets
Description: Advanced-formulation buprenorphine/naloxone sublingual tablets
Study NCT01848054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine sublingual tablets
Study NCT00792233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withdrawal of anti-TNF therapy
Description: Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
Study NCT04044209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
Study NCT04044209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle.
Study NCT03580382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib daily Until PD
Description: 1.0 mg daily
Study NCT01936558 — intervention group
Intervention type: OTHER
Intervention: Far infrared ray to the sole
Description: exposure 40-minute far infrared ray to the sole for each person/amputee.
Study NCT01775384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrasorb
Description: from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
Study NCT01775384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00427700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: 100mg PO on days 5-9 of the menstrual cycle
Study NCT00427700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Description: 100mg PO on days 5-9 of the menstrual cycle
Study NCT04277312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage
Description: The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.